Condition: Borderline Resectable Pancreatic Adenocarcinoma · Sponsor: Zhejiang University
This study is a Phase II clinical trial that plans to enroll 40 patients with borderline resectable pancreatic cancer harboring a KRAS G12D mutation, aiming to evaluate the efficacy of HRS-4642 in combination with Nimotuzumab and AG in borderline resectable pancreatic cancer. The study process includes a screening period (from the signing of the informed consent form until the first dose), a treatment period (from the first dose to the discontinuation of study treatment), and a follow-up period (safety follow-up and survival follow-up after the discontinuation of study treatment).
This description comes directly from the study's public registry record.
Tingbo Liang, MD · 86+19941463683 · liangtingbo@zju.edu.cn
Yiwen Chen, MD · 86+15088682641 · yiwenchen0705@126.com
Always discuss trial participation with your own doctor first.
| First Affiliated Hospital of Zhejiang University Schlool of Medicine | Hangzhou, Zhejiang, China | Not Yet Recruiting |
| the First Affiliated Hospital of Zhejiang University, School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07240766